Jul. 8 at 2:04 AM
$PTN $VRTX $CRNX $RYTM keep an eye on rare endo... Vertex’s massive
$10 billion all-cash acquisition of Crinetics is a flashing green light for the entire rare endocrine and obesity landscape. Big Pharma’s willingness to pay a massive premium for a pipeline centered on oral, targeted endocrinology therapeutics directly validates the enormous momentum and macro backdrop for Rhythm and eventually Palatin, both of which are developing next-generation oral and selective MC4R neuroendocrine assets. With Rhythm already sitting at a
$7.7 billion market cap, Vertex's move sets a concrete valuation floor for validated, next-gen endocrine pipelines. For a company like Palatin, trading at a stealth, microscopic
$19 million market cap while advancing its own oral small molecule toward the clinic, CRNX takeout highlights a glaring valuation disconnect ahead of PTN’s upcoming human trials. Just need an update on progress toward the clinic. Tick tock!
